VANCOUVER, April 8, 2020 /CNW/ - Precision NanoSystems (PNI), a global leader in enabling transformative nanomedicines today announced the appointment of Dr. Andrew Geall as the company's Chief Scientific Officer (CSO). Dr. Geall has over 20 years' experience in the development of drug delivery systems and is a pioneer in the development of rapid response RNA vaccines.
"Dr. Geall is a scientific leader who brings industry knowledge and deep expertise in developing RNA nanoparticle vaccines and therapeutics. With so many working tirelessly on Coronavirus vaccines and COVID therapeutics Andy will be able to immediately impact PNI and our clients due to his wealth of knowledge," said Dr. James Taylor, CEO and Co-Founder of PNI. "PNI is working with over 120 leading biopharmaceutical companies to develop vaccines, gene therapies, and small molecule formulations. Under Andrew's scientific leadership, we will accelerate our development cutting edge drug manufacturing and delivery technologies and build drug development collaborations with our partners."
Prior to joining PNI, Dr. Geall was RNA Vaccine Platform leader at Novartis Vaccines, where for 7 years he pioneered nanoparticle delivery of self-amplifying mRNA Vaccines in multiple disease targets and established the utility of the platform for pandemic rapid response. To support this work, Dr. Geall secured and was the Principle Investigator of a major contract from the Defense Advanced Research Project Agency. Most recently, Dr. Geall was member of Avidity Biosciences Executive Management Team, which established an antibody oligonucleotide conjugate platform, enabling clinical applications and collaborative partnerships in rare muscle diseases.
"Through my 20 years of developing advanced therapeutics, I have seen the challenges of transitioning nanomedicines research into development and then to patients. I have used the PNI platform in multiple projects and multiple companies since 2008. It represents a significant leap forward, allowing gene therapies, RNA vaccines, and advanced small molecule formulations to be rapidly developed and the platform is accessible to all drug developers," said Dr. Geall, CSO of PNI. "I have been on the PNI Scientific Advisory Board since 2017 and I'm very excited to have the opportunity to expand my role to work with the team and our global biopharmaceutical clients."
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
SOURCE Precision Nanosystems
For further information: Contact for further information or follow-up, Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: 1 888 618 0031, ext 140, mobile 1 778 877 5473